GOLPH3 predicts survival of colorectal cancer patients treated with 5-fluorouracil-based adjuvant chemotherapy

Journal of Translational Medicine

Xiangqian Su³  Jiafu Ji¹  Bin Dong²  Nan Zhang³  Zhendan Yao³  Chenghai Zhang³  Jiadi Xing³  Hong Yang³  Yiyuan Ma³  Maoxing Liu³  Ming Cui³  Jiabo Di³  Lei Chen³  Beihai Jiang³  Zaozao Wang³ 

[1] Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Surgery, Peking University Cancer Hospital & Institute, 100142 Beijing, China;Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital & Institute, 100142 Beijing, China;Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Minimally Invasive Gastrointestinal Surgery, Peking University Cancer Hospital & Institute, 52 Fucheng Road, Haidian District, 100142 Beijing, China

关键词: Prognosis;    Chemotherapy;    Colorectal cancer (CRC);    5-fluorouracil (5-FU);    GOLPH3;   

Others  :  822043
DOI  :  10.1186/1479-5876-12-15

 received in 2013-07-08, accepted in 2014-01-14,  发布年份 2014

【 摘 要 】

Background

Golgi phosphoprotein 3 (GOLPH3) has been validated as a potent oncogene involved in the progression of many types of solid tumors, and its overexpression is associated with poor clinical outcome in many cancers. However, it is still unknown the association of GOLPH3 expression with the prognosis of colorectal cancer (CRC) patients who received 5-fluorouracil (5-FU)-based adjuvant chemotherapy.

Methods

The expression of GOLPH3 was determined by qRT-PCR and immunohistochemistry in colorectal tissues from CRC patients treated with 5-FU based adjuvant chemotherapy after surgery. The association of GOLPH3 with clinicopathologic features and prognosis was analysed. The effects of GOLPH3 on 5-FU sensitivity were examined in CRC cell lines.

Results

GOLPH3 expression was elevated in CRC tissues compared with matched adjacent noncancerous tissues. Kaplan-Meier survival curves indicated that high GOLPH3 expression was significantly associated with prolonged disease-free survival (DFS, P = 0.002) and overall survival (OS, P = 0.011) in patients who received 5-FU-based adjuvant chemotherapy. Moreover, multivariate analysis showed that GOLPH3 expression was an independent prognostic factor for DFS in CRC patients treated with 5-FU-based chemotherapy (HR, 0.468; 95%CI, 0.222-0.987; P = 0.046). In vitro, overexpression of GOLPH3 facilitated the 5-FU chemosensitivity in CRC cells; while siRNA-mediated knockdown of GOLPH3 reduced the sensitivity of CRC cells to 5-FU-induced apoptosis.

Conclusions

Our results suggest that GOLPH3 is associated with prognosis in CRC patients treated with postoperative 5-FU-based adjuvant chemotherapy, and may serve as a potential indicator to predict 5-FU chemosensitivity.

【 授权许可】

   
2014 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Qaseem A, Denberg TD, Hopkins RH Jr, Humphrey LL, Levine J, Sweet DE, Shekelle P: Screening for colorectal cancer: a guidance statement from the American College of Physicians. Ann Intern Med 2012, 156:378-386.
• [2]Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N: Colorectal cancer. Lancet 2010, 375:1030-1047.
• [3]Longley DB, Harkin DP, Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003, 3:330-338.
• [4]Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C, Chollet P, Llory JF, Letourneau Y, Coudert B, et al.: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000, 18:136-147.
• [5]Gholam D, Giacchetti S, Brezault-Bonnet C, Bouchahda M, Hauteville D, Adam R, Ducot B, Ghemard O, Kustlinger F, Jasmin C, Levi F: Chronomodulated irinotecan, oxaliplatin, and leucovorin-modulated 5-Fluorouracil as ambulatory salvage therapy in patients with irinotecan- and oxaliplatin-resistant metastatic colorectal cancer. Oncologist 2006, 11:1072-1080.
• [6]Longley DB, Johnston PG: Molecular mechanisms of drug resistance. J Pathol 2005, 205:275-292.
• [7]Bell AW, Ward MA, Blackstock WP, Freeman HN, Choudhary JS, Lewis AP, Chotai D, Fazel A, Gushue JN, Paiement J, et al.: Proteomics characterization of abundant Golgi membrane proteins. J Biol Chem 2001, 276:5152-5165.
• [8]Dippold HC, Ng MM, Farber-Katz SE, Lee SK, Kerr ML, Peterman MC, Sim R, Wiharto PA, Galbraith KA, Madhavarapu S, et al.: GOLPH3 bridges phosphatidylinositol-4- phosphate and actomyosin to stretch and shape the Golgi to promote budding. Cell 2009, 139:337-351.
• [9]Scott KL, Chin L: Signaling from the Golgi: mechanisms and models for Golgi phosphoprotein 3-mediated oncogenesis. Clin Cancer Res 2010, 16:2229-2234.
• [10]Scott KL, Kabbarah O, Liang MC, Ivanova E, Anagnostou V, Wu J, Dhakal S, Wu M, Chen S, Feinberg T, et al.: GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature 2009, 459:1085-1090.
• [11]Zeng Z, Lin H, Zhao X, Liu G, Wang X, Xu R, Chen K, Li J, Song L: Overexpression of GOLPH3 promotes proliferation and tumorigenicity in breast cancer via suppression of the FOXO1 transcription factor. Clin Cancer Res 2012, 18:4059-4069.
• [12]Wang JH, Chen XT, Wen ZS, Zheng M, Deng JM, Wang MZ, Lin HX, Chen K, Li J, Yun JP, et al.: High expression of GOLPH3 in esophageal squamous cell carcinoma correlates with poor prognosis. PLoS One 2012, 7:e45622.
• [13]Li H, Guo L, Chen SW, Zhao XH, Zhuang SM, Wang LP, Song LB, Song M: GOLPH3 overexpression correlates with tumor progression and poor prognosis in patients with clinically N0 oral tongue cancer. J Transl Med 2012, 10:168. BioMed Central Full Text
• [14]Hu BS, Hu H, Zhu CY, Gu YL, Li JP: Overexpression of GOLPH3 is associated with poor clinical outcome in gastric cancer. Tumour Biol 2013, 34:515-520.
• [15]Hua X, Yu L, Pan W, Huang X, Liao Z, Xian Q, Fang L, Shen H: Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer. Diagn Pathol 2012, 7:127. BioMed Central Full Text
• [16]Zhou J, Xu T, Qin R, Yan Y, Chen C, Chen Y, Yu H, Xia C, Lu Y, Ding X, et al.: Overexpression of Golgi phosphoprotein-3 (GOLPH3) in glioblastoma multiforme is associated with worse prognosis. J Neurooncol 2012, 110:195-203.
• [17]Li XY, Liu W, Chen SF, Zhang LQ, Li XG, Wang LX: Expression of the Golgi phosphoprotein-3 gene in human gliomas: a pilot study. J Neurooncol 2011, 105:159-163.
• [18]Kunigou O, Nagao H, Kawabata N, Ishidou Y, Nagano S, Maeda S, Komiya S, Setoguchi T: Role of GOLPH3 and GOLPH3L in the proliferation of human rhabdomyosarcoma. Oncol Rep 2011, 26:1337-1342.
• [19]Han HB, Gu J, Zuo HJ, Chen ZG, Zhao W, Li M, Ji DB, Lu YY, Zhang ZQ: Let-7c functions as a metastasis suppressor by targeting MMP11 and PBX3 in colorectal cancer. J Pathol 2012, 226:544-555.
• [20]Chen L, Jiang B, Wang Z, Liu M, Ma Y, Yang H, Xing J, Zhang C, Yao Z, Zhang N, et al.: Expression and prognostic significance of GATA-binding protein 2 in colorectal cancer. Med Oncol 2013, 30:498.
• [21]Tay Y, Kats L, Salmena L, Weiss D, Tan SM, Ala U, Karreth F, Poliseno L, Provero P, Di Cunto F, et al.: Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs. Cell 2011, 147:344-357.
• [22]Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, De Murcia G, Murcia JM: Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem 1998, 273:33533-33539.
• [23]Shiozaki A, Kosuga T, Ichikawa D, Komatsu S, Fujiwara H, Okamoto K, Iitaka D, Nakashima S, Shimizu H, Ishimoto T, et al.: XB130 as an independent prognostic factor in human esophageal squamous cell carcinoma. Ann Surg Oncol 2013, 20:3140-3150.
• [24]Lodyga M, Bai XH, Kapus A, Liu M: Adaptor protein XB130 is a Rac-controlled component of lamellipodia that regulates cell motility and invasion. J Cell Sci 2010, 123:4156-4169.
• [25]Shiozaki A, Lodyga M, Bai XH, Nadesalingam J, Oyaizu T, Winer D, Asa SL, Keshavjee S, Liu M: XB130, a novel adaptor protein, promotes thyroid tumor growth. Am J Pathol 2011, 178:391-401.
• [26]Shi M, Huang W, Lin L, Zheng D, Zuo Q, Wang L, Wang N, Wu Y, Liao Y, Liao W: Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer. PLoS One 2012, 7:e41660.
• [27]Lu D, Chen S, Tan X, Li N, Liu C, Li Z, Liu Z, Stupack DG, Reisfeld RA, Xiang R: Fra-1 promotes breast cancer chemosensitivity by driving cancer stem cells from dormancy. Cancer Res 2012, 72:3451-3456.
• [28]Geng H, Rademacher BL, Pittsenbarger J, Huang CY, Harvey CT, Lafortune MC, Myrthue A, Garzotto M, Nelson PS, Beer TM, Qian DZ: ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21. Cancer Res 2010, 70:3239-3248.